Enliven Therapeutics Inc (ELVN)
SG&A Expense Growth
15.09%
Quarterly · Period ending:
ELVN SG&A Expense Growth
Latest reported15.09%period ending
Latest reported15.09%period ending
ELVN Quarterly SG&A Growth (QoQ) (0.00% → 15.09%)
Latest values, visible window
High-resolution chart · PNG
ELVN sg&a expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | SG&A Expense Growth |
|---|---|
| 15.0925% | |
| -45.2761% | |
| 89.7831% | |
| -3.1298% | |
| 4.3395% | |
| 10.1426% | |
| 6.2306% | |
| 0.5712% | |
| -3.9887% | |
| 24.7305% | |
| 44.3447% | |
| -8.4634% | |
| -19.5461% | |
| 130.824% | |
| -36.6828% | |
| 187.7665% | |
| -33.3539% | |
| 5.7479% | |
| -52.7177% | |
| 5.4723% | |
| -2.2293% | |
| 21.1887% | |
| -12.4958% | |
| 21.7016% | |
| 56.0616% | |
| 1.1681% | |
| -11.4877% | |
| 46.1797% | |
| 87.8549% | |
| 0% |